Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Parallel, Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Fugan Ointment (ZL-3101) in Subjects With Subacute Eczema

Trial Profile

A Multi-center, Randomized, Double-blind, Parallel, Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Fugan Ointment (ZL-3101) in Subjects With Subacute Eczema

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2018

At a glance

  • Drugs ZL 3101 (Primary)
  • Indications Eczema
  • Focus Therapeutic Use
  • Sponsors ZAI Lab
  • Most Recent Events

    • 24 Aug 2018 Primary endpoint has not been met. (Eczema Area and Severity Index (EASI) score changes from baseline to day 21), according to a ZAI Lab media release.
    • 24 Aug 2018 According to a ZAI Lab media release, based on the top-line results of this study, the company has decided to discontinue the development of ZL-3101 (Fugan) for the treatment of atopic dermatitis (AD). The study showed that drug was safe and well-tolerated, however, the treatment showed no efficacy differences between placebo and ZL-3101 .
    • 25 May 2018 According to a Zai Lab media release, topline results from this study are expected in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top